Captor Therapeutics to Present at the 4th Annual Targeted Protein Degradation Summit
Wrocław, Poland, October 26, 2021 - Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company focused on the development of novel protein degradation drugs for cancer and autoimmune diseases, today announces that Chief Scientific Officer Dr. Michal Walczak will present at the 4th Annual Targeted Protein Degradation (TPD) Summit, being held virtually from 26th to 29th October, 2021.
The presentation, entitled "New Opportunities in Targeting Cancer Resistance Mechanisms with TPD", will discuss a case study of MCL-1 degraders, one of Captor’s high-potential pipeline projects, disclosed last month. MCL-1 degradation is an excellent example of leveraging TPD to overcome cancer resistance. Dr. Michał Walczak will present the results demonstrating desired pharmacodynamic effects, including degradation of MCL-1 and strong induction of apoptosis in vivo in tumour-bearing mice in a leukaemia model (MV4-11).
Details of the presentation:
- Title: New Opportunities in Targeting Cancer Resistance Mechanisms with TPD
- Presenting: Dr. Michal Walczak
- Thursday, 28 October 2021 at 12 pm EST / 6 pm CET
- To register for the event, click here
A copy of the slides will be available on Captor Therapeutics’ website shortly after the event.
To request a one-on-one meeting with the Captor team, please contact us at firstname.lastname@example.org.
About Captor Therapeutics
Captor Therapeutics is a biopharmaceutical company focused on leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough drug candidates in diseases with high unmet medical needs. TPD is a revolutionary approach to developing new drugs that can address novel molecular targets which are deemed “undruggable” with classical drug development approaches, as well as providing additional treatment options for diseases where existing drugs fail to provide optimal medical benefit. Captor is currently developing therapeutics for undertreated severe conditions, including malignancies and autoimmune diseases.
More information on Captor Therapeutics is available at: http://www.captortherapeutics.com
For further information, please contact:
Polish Media and Investor relations:
Point of View
+48 601 155 582
International Investor Relations:
Guillaume van Renterghem
+41 (0)76 735 01 31